FGF-2 protects cardiomyocytes from doxorubicin damage via protein kinase C-dependent effects on efflux transporters

Cardiovascular Research

Volumn 98, Issue 1, 2013, Pages 56-63

  Wang, Jie ^a   Nachtigal, Mark W ^a   Kardami, Elissavet ^a   Cattini, Peter A ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cardiac myocytes; Doxorubicin; Drug resistance; Efflux transport; FGF 2

Indexed keywords

CALCEIN; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 2; LACTATE DEHYDROGENASE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PROTEIN KINASE C; RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL DEATH; CELL SELECTION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; HEART MUSCLE CELL; HEART PROTECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; CYCLOSPORINE; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 2; L-LACTATE DEHYDROGENASE; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MYOCYTES, CARDIAC; P-GLYCOPROTEIN; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84875185465     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt011     Document Type: Article

References (43)

1. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 2012;52:1213-1225.
2. Peng X, Chen B, Lim CC, Sawyer DB. The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. Mol Interv 2005;5:163-171.
3. Karukstis KK, Thompson EH, Whiles JA, Rosenfeld RJ. Deciphering the fluorescence signature of daunomycin and doxorubicin. Biophys Chem 1998;73:249-263.
4. Detillieux KA, Sheikh F, Kardami E, Cattini PA. Biological activities of fibroblast growth factor-2 in the adult myocardium. Cardiovasc Res 2003;57:8-19.
5. Detillieux KA, Cattini PA, Kardami E. Beyond angiogenesis: The cardioprotective potential of fibroblast growth factor-2. Can J Physiol Pharmacol 2004;82:1044-1052.
6. Virag JA, Rolle ML, Reece J, Hardouin S, Feigl EO, Murry CE. Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function. Am J Pathol 2007;171:1431-1440.
7. Jiang ZS, Srisakuldee W, Soulet F, Bouche G, Kardami E. Non-angiogenic FGF-2 protects the ischemic heart from injury, in the presence or absence of reperfusion. Cardiovasc Res 2004;62:154-166.
8. Kardami E, Detillieux K, Ma X, Jiang Z, Santiago JJ, Jimenez SK et al. Fibroblast growth factor-2 and cardioprotection. Heart Fail Rev 2007;12:267-277.
9. Jiang ZS, Padua RR, Ju H, Doble BW, Jin Y, Hao J et al. Acute protection of ischemic heart by FGF-2: involvement of FGF-2 receptors and protein kinase C. Am J Physiol Heart Circ Physiol 2002;282:H1071-H1080.
10. Padua RR, Merle PL, Doble BW, Yu CH, Zahradka P, Pierce GN et al. FGF-2-induced negative inotropism and cardioprotection are inhibited by chelerythrine: involvement of sarcolemmal calcium-independent protein kinase C. J Mol Cell Cardiol 1998;30: 2695-2709.
11. Duquesnes N, Lezoualc'h F, Crozatier B. PKC-delta and PKC-epsilon: Foes of the same family or strangers? J Mol Cell Cardiol 2011;51:665-673.
12. Jimenez SK, Sheikh F, Jin Y, Detillieux KA, Dhaliwal J, Kardami E et al. Transcriptional regulation of FGF-2 gene expression in cardiac myocytes. Cardiovasc Res 2004;62: 548-557.
13. House SL, Bolte C, Zhou M, Doetschman T, Klevitsky R, Newman G et al. Cardiacspecific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation 2003;108: 3140-3148.
14. Coleman AB. Positive and negative regulation of cellular sensitivity to anti-cancer drugs by FGF-2. Drug Resist Updat 2003;6:85-94.
15. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-1654.
16. Katayama K, Yoshioka S, Tsukahara S, Mitsuhashi J, Sugimoto Y. Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther 2007;6:2092-2102.
17. Jose M, Thomas SV. Role of multidrug transporters in neurotherapeutics. Ann Indian Acad Neurol 2009;12:89-98.
18. Mordente A, Meucci E, Silvestrini A, Martorana GE, Giardina B. New developments in anthracycline-induced cardiotoxicity. Curr Med Chem 2009;16:1656-1672.
19. Couture L, Nash JA, Turgeon J. The ATP-binding cassette transporters and their implication in drug disposition: A special look at the heart. Pharmacol Rev 2006;58: 244-258.
20. Jungsuwadee P, Nithipongvanitch R, Chen Y, Oberley TD, Butterfield DA, St Clair DK et al. Mrp1 localization and function in cardiac mitochondria after doxorubicin. Mol Pharmacol 2009;75:1117-1126.
21. Lampidis TJ, Henderson IC, Israel M, Canellos GP. Structural and functional effects of adriamycin on cardiac cells in vitro. Cancer Res 1980;40:3901-3909.
22. Barnabe N, Marusak RA, Hasinoff BB. Prevention of doxorubicin-induced damage to rat heart myocytes by arginine analog nitric oxide synthase inhibitors and their enantiomers. Nitric Oxide 2003;9:211-216.
23. Howard PH, Payne S, Wong L, Gonzalez B, Lewis W. Lactate dehydrogenase activity in cultured neonatal rat heart cells exposed to doxorubicin. Exp Mol Pathol 1988;48: 311-316.
24. Ikegami E, Fukazawa R, Kanbe M,Watanabe M, Abe M, Kamisago M et al. Edaravone, a potent free radical scavenger, prevents anthracycline-induced myocardial cell death. Circ J 2007;71:1815-1820.
25. Lewis W, Gonzalez B. Anthracycline effects on actin and actin-containing thin filaments in cultured neonatal rat myocardial cells. Lab Invest 1986;54:416-423.
26. Sofronescu AG, Jin Y, Cattini PA. A myocyte enhancer factor 2 (MEF2) site located in a hypersensitive region of the FGF16 gene locus is required for preferential promoter activity in neonatal cardiac myocytes. DNA Cell Biol 2008;27:173-182.
27. Lu SY, Sontag DP, Detillieux KA, Cattini PA. FGF-16 is released from neonatal cardiac myocytes and alters growth-related signaling: A possible role in postnatal development. Am J Physiol Cell Physiol 2008;294:C1242-C1249.
28. Sofronescu AG, Detillieux KA, Cattini PA. FGF-16 is a target for adrenergic stimulation through NF-kappaB activation in postnatal cardiac cells and adult mouse heart. Cardiovasc Res 2010;87:102-110.
29. Hasinoff BB, Patel D, Wu X. The Dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin. Cardiovasc Toxicol 2013;13:33-47.
30. Tang F, Borchardt RT. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE. Pharm Res 2002;19:787-793.
31. Estevez MD, Wolf A, Schramm U. Effect of PSC 833, verapamil and amiodarone on adriamycin toxicity in cultured rat cardiomyocytes. Toxicol In Vitro 2000;14:17-23.
32. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 2000;6:4186-4191.
33. Tarasenko N, Cutts SM, Phillips DR, Inbal A, Nudelman A, Kessler-Icekson G et al. Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor. PLoS One 2012;7: e31393.
34. Zhang YW, Shi J, Li YJ, Wei L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz) 2009;57:435-445.
35. Griffiths EJ, Halestrap AP. Protection by cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol 1993;25: 1461-1469.
36. Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA et al. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther 2008;324:95-102.
37. Song S, Wientjes MG, Gan Y, Au JL. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 2000;97: 8658-8663.
38. Alavi AS, Acevedo L, Min W, Cheresh DA. Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. Cancer Res 2007;67:2766-2772.
39. Coleman AB, Momand J, Kane SE. Basic fibroblast growth factor sensitizes NIH 3T3 cells to apoptosis induced by cisplatin. Mol Pharmacol 2000;57:324-333.
40. Cui YJ, Cheng X, Weaver YM, Klaassen CD. Tissue distribution, gender-divergent expression, ontogeny, and chemical induction of multidrug resistance transporter genes (Mdr1a, Mdr1b, Mdr2) in mice. Drug Metab Dispos 2009;37:203-210.
41. Coleman AB, Metz MZ, Donohue CA, Schwarz RE, Kane SE. Chemosensitization by fibroblast growth factor-2 is not dependent upon proliferation, S-phase accumulation, or p53 status. Biochem Pharmacol 2002;64:1111-1123.
42. Rittierodt M, Tschernig T, Harada K. Modulation of multidrug-resistance- associated P-glycoprotein in human U-87 MG and HUV-ECC cells with antisense oligodeoxynucleotides to MDR1 mRNA. Pathobiology 2004;71:123-128.
43. Srisakuldee W, Jeyaraman MM, Nickel BE, Tanguy S, Jiang ZS, Kardami E. Phosphorylation of connexin-43 at serine 262 promotes a cardiac injury-resistant state. Cardiovasc Res 2009;83:672-681.